Harnessing the power of Imaging Phenomics

At Median, we’re transforming the science of medical imaging. By harnessing the power of Imaging Phenomics we can improve current treatment, enhance diagnosis and accelerate development of next generation therapies, helping make a healthier world for millions.

The fight against disease is a joint effort

While our expertise and resources are unique, we don’t work alone. The fight against disease is a joint effort and the spirit of cooperation is found in everything we do. Whether working in clinical trials or patient care and treatment, we share the same single-minded goal. To defeat the diseases that still touch so many lives.

Pushing the boundaries of imaging technology

At Median we’re determined to push the boundaries of what imaging technology can achieve, to help develop next generation treatments with the potential to save or improve the lives of millions.

CEO’s message


Fredrik Brag talks about how we’re looking to change the game. To transform the landscape in which we work and create a new world of possibilities for biopharma companies and healthcare professionals alike.

Read more

The Imaging Phenomics Company®

Median Technologies is the Imaging Phenomics Company®. Learn about our MediScan® portfolio for Patient Care, our Lesion Management Solution (LMS) technology and iBiopsy®, our Imaging Biomarker Phenotyping System.

Watch

News

21 February 2018

Median Technologies Announces Preliminary Full Year 2017 Unaudited Financial Results

Median Technologies Announces Preliminary Full Year 2017 Unaudited Financial Results:
Full year 2017 revenues increased by 21% to €7.69 million from €6.35 million in 2016 – Net new business of €14.69 million in 2017, increased backlog to €23 million as of December 31, 2017 – Cash and cash equivalents are expected to be approximately €28.29 million as of December 31, 2017

13 February 2018

Median Technologies announces results of deep learning study for enhanced prostate segmentation – helping to advance precision medicine

Median Technologies announces results of deep learning study for enhanced prostate segmentation – helping to advance precision medicine. Results to be presented at the SPIE Medical Imaging conference in Houston, TX, USA

16 January 2018

Financial Communications Schedule for the First Half of 2018

Median Technologies (Paris:ALMDT), the industry-leading Imaging Phenomics Company®, announces the publication date for its 2017 results.

4 January 2018

Median Technologies ranks in Deloitte Technology Fast 500™ EMEA for 2017

Median Technologies ranks in Deloitte Technology Fast 500™ EMEA for 2017. Listing recognizes technology companies that have achieved the fastest rates of revenue growth in Europe, the Middle East, and Africa (EMEA) during the past four years.

14 December 2017

Median Technologies launches iSee®– a comprehensive technology platform to enhance medical imaging analysis in clinical trials

Press release – For immediate release – 5:45pm CET

Median Technologies launches iSee®– a comprehensive technology platform to enhance medical imaging analysis in clinical trials – New platform enables high quality, accurate and predictive data for critical imaging endpoints

1/5

Opinion

9 January 2018
The Value of Standardized Quality and Performance Metrics in Clinical Trials

The Value of Standardized Quality and Performance Metrics in Clinical Trials

The Value of Standardized Quality and Performance Metrics in Clinical Trials It’s not just tumor measurements that matter! Quality and Performance Measurements are…

12 October 2017
Different Types of Imaging Criteria: Morphological Measures

Different Types of Imaging Criteria: Morphological Measures

Different Types of Imaging Criteria: Morphological Measures In oncology clinical trials, therapy is generally assessed using imaging response criteria involving imaging biomarkers. Imaging…

11 July 2017
Super Resolution Imaging – For Better Medical Image Analysis

Super Resolution Imaging – For Better Medical Image Analysis

Super Resolution Imaging – For Better Medical Image Analysis If you are fan of science fiction films and you are 40+ like me,…

30 May 2017
Why Cultural Fit Matters when Selecting an Imaging CRO

Why Cultural Fit Matters when Selecting an Imaging CRO

Why Cultural Fit Matters when Selecting an Imaging CRO In the clinical trials process, high quality imaging used as surrogate endpoints significantly improves…

16 May 2017
Minimizing Variability in Imaging Reads for Clinical trials

Minimizing Variability in Imaging Reads for Clinical trials

Minimizing Variability in Imaging Reads for Clinical trials In oncology, response to treatment is typically assessed by measuring tumor size and growth over…

1/5
Imaging for patient care

Identifying treatments that work

Imaging biomarkers provide a unique insight into treatment progress at every stage of a disease. In cancer for instance, comprehensive quantitative information plays an invaluable role in defining, tracking and measuring treatment outcomes. Providing clear evidence of what works and what doesn’t.

Read more

Imaging for clinical trials

Advancing treatments of the future

Working with biopharmaceutical companies, and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments

Read more

Ibiopsy®

Powering the phenomics revolution

We’re changing the game; transforming the landscape. We’re capturing the power of big data and unique biomarker imaging technology to create a new world of possibilities for biopharma and healthcare professionals alike. Our iBiopsy® platform opens up the field of phenomics, driving the science of precision medicine.

Read more

Investors

Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Read more

Stock Market Data

TICKER: ALMDT ISIN: FR0011049824
Get in touch

europe

Median Technologies
Les Deux Arcs, Bât B
1800, route des Crêtes
06560 Valbonne
France

Get in touch

Get in touch





Jobs at Median

United States

Legal address
Median Technologies Inc
C/O Pramex International
1251 Avenue of the Americas
3rd Floor
New York NY 10020

US offices

Median Technologies Inc
300 TradeCenter
Suite 5610
Woburn MA 01801

Cookies help us deliver our services. By using our services, you agree to our use of cookies.